Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

TSXV:BTI.H - Post Discussion

biOasis Technologies Ord Shs > Prothena
View:
Post by AlfredSisley on Dec 14, 2020 1:37pm

Prothena

What's going on here with the 3 addtional options? Will the time limit be extended again?

What about the exclusive deal on the undisclosed neurodegenerative disease target?

Should this exclusive licensing deal even be in our pipeline given we've sold milestone payments AND future royalties to XOMA?
Comment by JDavenport on Dec 14, 2020 2:13pm
AlfredSisley, go read the XOMA 10K and Bioasis' reports and PRs, for goodness sakes. YES, PROTHENA SHOULD BE, MUST BE, AND WILL BE CONTAINED WITHIN BIOASIS' REPORTING. Nobody likes tax loss selling. Nobody likes a 28¢ share price. Very few will buy from the offer in December. (No offense, just business.) Shareholder meltdowns are born of ignorance about Bioasis and xB3. They are ...more  
biOasis Technologies Ord Shs
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities